(NASDAQ: NAGE) Niagen Bioscience's forecast annual revenue growth rate of 18.38% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 130.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.85%.
Niagen Bioscience's revenue in 2025 is $107,925,000.On average, 2 Wall Street analysts forecast NAGE's revenue for 2025 to be $9,775,315,054, with the lowest NAGE revenue forecast at $9,743,807,189, and the highest NAGE revenue forecast at $9,806,822,919. On average, 2 Wall Street analysts forecast NAGE's revenue for 2026 to be $11,791,818,401, with the lowest NAGE revenue forecast at $11,768,187,503, and the highest NAGE revenue forecast at $11,815,449,300.
In 2027, NAGE is forecast to generate $14,233,677,923 in revenue, with the lowest revenue forecast at $14,233,677,923 and the highest revenue forecast at $14,233,677,923.